Shattuck Labs Q2 net loss $27.4M; cash runway into H2 2024; SL-172154 combo trials starting

Shattuck Labs, Inc.

2022-Q2 EPS reported -$1.22 revenue$50,000

Cash and equivalents $214.2M (Dec 2021: $268.8M); operations funded into second half of 2024.
Net loss $27.4M ($0.65/share) vs $23.6M ($0.56) in Q2 2021; R&D expense rose to $23.0M from $14.9M.
SL-172154 dose escalation in ovarian cancer reached 10.0 mg/kg; combo with liposomal doxorubicin starts Q3 2022.
Phase 1A/B of SL-172154 in AML/HR-MDS enrolling; initial monotherapy and combo data expected 1H 2023.
New clinical candidate from ARC or GADLEN platform expected to be announced in second half of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.